Page last updated: 2024-08-26

bosentan anhydrous and Orphan Diseases

bosentan anhydrous has been researched along with Orphan Diseases in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jachowicz, R; Krupa, A; Majda, D; Mozgawa, W; Szlęk, J1
de Barros, CM; Papoila, AL1

Other Studies

2 other study(ies) available for bosentan anhydrous and Orphan Diseases

ArticleYear
Physicochemical Properties of Bosentan and Selected PDE-5 Inhibitors in the Design of Drugs for Rare Diseases.
    AAPS PharmSciTech, 2017, Volume: 18, Issue:4

    Topics: Bosentan; Drug Design; Humans; Hypertension, Pulmonary; Phosphodiesterase 5 Inhibitors; Rare Diseases; Sildenafil Citrate; Sulfonamides; Tadalafil

2017
Therapeutic profile of orphan medicines.
    Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:4

    Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Antineoplastic Agents; Bosentan; Caffeine; Central Nervous System Stimulants; Child; Child, Preschool; Citrates; Cross-Sectional Studies; Drug Labeling; Drug Prescriptions; Drug Utilization; Female; Humans; Immunologic Factors; Infant; Infant, Newborn; Male; Middle Aged; Orphan Drug Production; Pharmacy Service, Hospital; Portugal; Rare Diseases; Sulfonamides

2007